CN106232581A - 用于靶向化疗的非铂基抗癌化合物 - Google Patents
用于靶向化疗的非铂基抗癌化合物 Download PDFInfo
- Publication number
- CN106232581A CN106232581A CN201480066862.2A CN201480066862A CN106232581A CN 106232581 A CN106232581 A CN 106232581A CN 201480066862 A CN201480066862 A CN 201480066862A CN 106232581 A CN106232581 A CN 106232581A
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- ring
- group
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SFVPYJWMKOBKAD-RKDXNWHRSA-N CC(C)[C@@H](CC[C@@H](C)NC)S Chemical compound CC(C)[C@@H](CC[C@@H](C)NC)S SFVPYJWMKOBKAD-RKDXNWHRSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/52—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111465211.9A CN114380700A (zh) | 2013-10-08 | 2014-10-08 | 用于靶向化疗的非铂基抗癌化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887988P | 2013-10-08 | 2013-10-08 | |
| US61/887988 | 2013-10-08 | ||
| PCT/CA2014/050974 WO2015051458A1 (en) | 2013-10-08 | 2014-10-08 | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111465211.9A Division CN114380700A (zh) | 2013-10-08 | 2014-10-08 | 用于靶向化疗的非铂基抗癌化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106232581A true CN106232581A (zh) | 2016-12-14 |
Family
ID=52812401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480066862.2A Pending CN106232581A (zh) | 2013-10-08 | 2014-10-08 | 用于靶向化疗的非铂基抗癌化合物 |
| CN202111465211.9A Pending CN114380700A (zh) | 2013-10-08 | 2014-10-08 | 用于靶向化疗的非铂基抗癌化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111465211.9A Pending CN114380700A (zh) | 2013-10-08 | 2014-10-08 | 用于靶向化疗的非铂基抗癌化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10463662B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3578176A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6765302B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102307387B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN106232581A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014334461B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2926571C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015051458A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
| US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| US12233062B2 (en) | 2018-09-26 | 2025-02-25 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| EP3484528B1 (en) | 2016-07-18 | 2020-11-25 | Janssen Pharmaceutica NV | Tau pet imaging ligands |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219440A1 (en) * | 2002-04-17 | 2003-11-27 | Annette Tobia | 3-deoxyglucosone and skin |
| US20060089316A1 (en) * | 2004-10-25 | 2006-04-27 | Brown Truman R | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof |
| CN101203509A (zh) * | 2005-02-16 | 2008-06-18 | 先灵公司 | 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶 |
| DK200801600A (en) * | 2008-11-17 | 2010-05-18 | Engkilde Kaare | Method for treatment of inflammatory diseases |
| WO2014094178A1 (en) * | 2012-12-20 | 2014-06-26 | Lu qing-bin | Radiosensitizer compounds for use in combination with radiation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3822261A (en) * | 1972-10-30 | 1974-07-02 | Dow Chemical Co | 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines |
| IL112235A (en) * | 1994-01-03 | 2000-06-29 | Acea Pharm Inc | 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them |
| DE102004054545A1 (de) * | 2004-09-16 | 2006-04-06 | Max-Delbrück-Centrum für Molekulare Medizin | Änderung des Beladungszustandes von MHC-Molekülen |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| CN101611007A (zh) | 2006-12-20 | 2009-12-23 | 先灵公司 | 新颖的jnk抑制剂 |
| ES2569660T3 (es) * | 2007-06-08 | 2016-05-12 | Mannkind Corporation | Inhibidores de la IRE-1alfa |
| EP2188276B1 (en) * | 2007-08-16 | 2012-03-28 | F. Hoffmann-La Roche AG | Substituted hydantoins |
| EP2493862B1 (en) * | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| WO2012096813A1 (en) * | 2011-01-11 | 2012-07-19 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
-
2014
- 2014-10-08 KR KR1020167012036A patent/KR102307387B1/ko not_active Expired - Fee Related
- 2014-10-08 EP EP19188591.2A patent/EP3578176A1/en not_active Withdrawn
- 2014-10-08 CN CN201480066862.2A patent/CN106232581A/zh active Pending
- 2014-10-08 JP JP2016522040A patent/JP6765302B2/ja not_active Expired - Fee Related
- 2014-10-08 WO PCT/CA2014/050974 patent/WO2015051458A1/en not_active Ceased
- 2014-10-08 CA CA2926571A patent/CA2926571C/en active Active
- 2014-10-08 EP EP14852850.8A patent/EP3055287B1/en active Active
- 2014-10-08 AU AU2014334461A patent/AU2014334461B2/en not_active Ceased
- 2014-10-08 CN CN202111465211.9A patent/CN114380700A/zh active Pending
- 2014-10-08 US US15/028,169 patent/US10463662B2/en active Active
-
2019
- 2019-09-18 US US16/574,800 patent/US11446294B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030219440A1 (en) * | 2002-04-17 | 2003-11-27 | Annette Tobia | 3-deoxyglucosone and skin |
| US20060089316A1 (en) * | 2004-10-25 | 2006-04-27 | Brown Truman R | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof |
| CN101203509A (zh) * | 2005-02-16 | 2008-06-18 | 先灵公司 | 具有cxcr3拮抗剂活性的胺-连接的吡啶基和苯基取代的哌嗪-哌啶 |
| DK200801600A (en) * | 2008-11-17 | 2010-05-18 | Engkilde Kaare | Method for treatment of inflammatory diseases |
| WO2014094178A1 (en) * | 2012-12-20 | 2014-06-26 | Lu qing-bin | Radiosensitizer compounds for use in combination with radiation |
Non-Patent Citations (3)
| Title |
|---|
| H A MILMA等: "Apparent correlation between structure and carcinogenicity of phenylenediamines and related compounds", 《ENVIRON HEALTH PERSPECT》 * |
| MARIKO MURATA等: "Oxidative DNA damage induced by hair dye components ortho-phenylenediamines and the enhancement by superoxide dismutase", 《MUTATION RESEARCH》 * |
| ROBERT GODEMANN等: "Fragment-Based Discovery of BACE1 Inhibitors Using Functional Assays", 《BIOCHEMISTRY》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
| US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| US12233062B2 (en) | 2018-09-26 | 2025-02-25 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2926571A1 (en) | 2015-04-16 |
| AU2014334461A1 (en) | 2016-04-28 |
| KR102307387B1 (ko) | 2021-09-30 |
| JP6765302B2 (ja) | 2020-10-07 |
| KR20160070784A (ko) | 2016-06-20 |
| US10463662B2 (en) | 2019-11-05 |
| US20160235743A1 (en) | 2016-08-18 |
| AU2014334461B2 (en) | 2019-06-13 |
| JP2016534048A (ja) | 2016-11-04 |
| EP3055287A1 (en) | 2016-08-17 |
| US11446294B2 (en) | 2022-09-20 |
| EP3578176A1 (en) | 2019-12-11 |
| CN114380700A (zh) | 2022-04-22 |
| CA2926571C (en) | 2022-05-17 |
| WO2015051458A1 (en) | 2015-04-16 |
| EP3055287A4 (en) | 2017-04-12 |
| US20200009133A1 (en) | 2020-01-09 |
| EP3055287B1 (en) | 2019-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11446294B2 (en) | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy | |
| CN105164107B (zh) | 用于与放射结合使用的放射增敏剂化合物 | |
| Tan et al. | Nuclear permeable ruthenium (II) β-carboline complexes induce autophagy to antagonize mitochondrial-mediated apoptosis | |
| Cloonan et al. | Detailed biological profiling of a photoactivated and apoptosis inducing pdppz ruthenium (II) polypyridyl complex in cancer cells | |
| CA3138197A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| ES2898704T3 (es) | Compuestos de platino funcionalizados con monomaleimida para la terapia del cáncer | |
| WO2012064898A1 (en) | Singleton inhibitors of sumoylation enzymes and methods for their use | |
| US9867807B2 (en) | Compositions and methods for drug-sensitization or inhibition of a cancer cell | |
| JP2019529475A (ja) | Dna損傷剤とdna−pk阻害剤との組合せ物を使用する、がんを処置するための方法 | |
| WO2020024969A1 (en) | Iridium (iii) complexes containing n-heterocyclic carbene ligand, synthesis, and their use thereof in cancer treatment | |
| Sutradhar et al. | Harnessing the zinc (ii) bis-terpyridine complex to overcome drug resistance: mechanistic insights into antibacterial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |
|
| RJ01 | Rejection of invention patent application after publication |